Study guide
12.2 Biostatistics and Literature Evaluation
Board Certified Critical Care Pharmacist Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pathophysiology and Recognition of Critical Illness
1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness
2 Chapter 2: Medical Devices and Circulatory Support
2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care
3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management
3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation
4 Chapter 4: Vasoactive and Inotropic Therapy in Shock
4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock
5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)
5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness
6 Chapter 6: Cardiovascular Emergencies
6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias
7 Chapter 7: Pulmonary and Infectious Diseases in the ICU
7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU
8 Chapter 8: Neurocritical Care
8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury
9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies
9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy
10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition
10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral
11 Chapter 11: Quality, Safety, and Clinical Guidelines
11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions
12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine
12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management
13 Chapter 13: Treatment Planning and Care Coordination
13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education
12.2 Biostatistics and Literature Evaluation
Key Takeaways Explain This Topic AI
Nominal data uses unordered categories (e.g., gender, mortality), while ordinal data has a set order but unequal intervals (e.g., pain scale).
Parametric tests (e.g., Student's t-test, ANOVA) require continuous data with a normal distribution.
Non-parametric tests (e.g., Mann-Whitney U, Kruskal-Wallis) are used for ordinal data or non-normally distributed continuous data.
Type I error (alpha) occurs when a true null hypothesis is incorrectly rejected (false positive).
A confidence interval for a ratio (RR, OR, HR) that includes 1.0 is not statistically significant.
Last updated: July 2026
Biostatistics and Clinical Literature Evaluation
A critical care pharmacist must rapidly analyze and apply clinical trial results to bed-side patient care. This requires a sophisticated understanding of biostatistics, data structures, and literature evaluation. Selecting and interpreting statistical analyses ensures that clinical protocols and patient-specific interventions are grounded in solid scientific evidence rather than random variation.
Classification of Data Types
Data are the building blocks of clinical research and are categorized into discrete (categorical) and continuous (scale) data. The mathematical properties of the data dictate the statistical tests that can be legally performed.
Discrete (Categorical) Data
Discrete data are divided into distinct categories where values cannot be subdivided.
Nominal Data: Categorical variables with no inherent quantitative value or logical order. Examples:
Survival status at day 28 (alive vs. dead).
Primary pathogen group (Gram-positive vs. Gram-negative vs. fungal).
Development of ventilator-associated pneumonia (yes vs. no).
Blood type (A, B, AB, O).
Ordinal Data: Categorical variables that possess a logical order or ranking, but the mathematical distance between the ranks is not uniform or quantifiable. Examples:
Richmond Agitation-Sedation Scale (RASS) score, ranging from -5 (unarousable) to +4 (combative).
Critical-Care Pain Observation Tool (CPOT) score (0 to 8).
Glasgow Coma Scale (GCS) score (3 to 15).
New York Heart Association (NYHA) functional class (I, II, III, IV).
APACHE II severity score.
Continuous (Scale) Data
Continuous data can take on any value along a specific range and have consistent, measurable intervals between data points.
Interval Data: Continuous data with consistent intervals, but without a true absolute zero point (zero does not indicate the absence of the property). Example: Temperature in Celsius or Fahrenheit (0 degrees does not mean there is no heat).
Ratio Data: Continuous data with a true absolute zero point, where zero represents the complete absence of the measured property. This allows for ratio comparisons (e.g., 10 mg is twice as much as 5 mg). Examples:
Mean arterial pressure (MAP) in mmHg.
Vasoactive infusion rates (e.g., norepinephrine dose in mcg/kg/min).
Serum creatinine concentration (mg/dL).
Urinary output (mL/kg/hour).
Intracranial pressure (ICP) in mmHg.
Volume of distribution ( V d V_d V d ) and clearance ( C l Cl Cl ) of an antibiotic.
Parametric vs. Non-parametric Statistical Tests
Statistical tests are selected based on the data type, the number of comparative groups, and the distribution of the data.
Parametric Tests
Parametric tests assume that the data are continuous and follow a normal (Gaussian, bell-shaped) distribution, and that there is homogeneity of variance between the groups. These tests are mathematically powerful because they evaluate the actual values (means and standard deviations).
Student's t-test (Independent samples): Compares the means of two independent groups (e.g., comparing mean MAP in patients randomized to norepinephrine vs. vasopressin).
Paired t-test: Compares the means of two related or matched groups (e.g., comparing a patient's arterial pH before and after receiving a sodium bicarbonate infusion).
Analysis of Variance (ANOVA): Compares the means of three or more independent groups (e.g., comparing mean arterial blood gas values between patients randomized to three different ventilator modes).
Non-parametric Tests
Non-parametric tests do not assume a normal distribution (distribution-free). They are used for ordinal data, categorical data, or continuous data that are skewed (non-normally distributed). Instead of comparing means, these tests analyze the ranks of the data.
Mann-Whitney U Test (Wilcoxon Rank-Sum Test): Compares two independent groups (e.g., comparing median days of mechanical ventilation between a propofol group and a dexmedetomidine group, where ventilation days are skewed).
Wilcoxon Signed-Rank Test: Compares two paired or related groups (e.g., comparing median CPOT pain scores in the same patient before and after receiving intravenous fentanyl).
Kruskal-Wallis Test: Compares three or more independent groups (e.g., comparing median ICU length of stay across three different sedation protocols).
Chi-square ( χ 2 \chi^2 χ 2 ) Test: Compares the proportions of nominal data between two or more independent groups. It requires a large sample size (expected cell counts in a contingency table must be ≥ 5 \ge 5 ≥ 5 ). E.g., comparing 30-day mortality rates between hydrocortisone and placebo groups in septic shock.
Fisher's Exact Test: Compares proportions of nominal data when sample sizes are small (any cell in the contingency table has an expected count < 5 < 5 < 5 ). E.g., comparing the rate of a rare adverse event, like propofol infusion syndrome (PRIS), between low-dose and high-dose propofol groups.
McNemar's Test: Compares proportions of paired nominal data (e.g., checking presence of delirium [yes/no] before and after a sedation vacation in the same cohort).
- Data Type 2 Groups (Independent) 2 Groups (Paired/Related) ≥ 3 \ge 3 ≥ 3 Groups (Independent)
- Continuous (Normal) Student's t-test Paired t-test One-way ANOVA
- Continuous (Skewed) or Ordinal Mann-Whitney U test Wilcoxon signed-rank test Kruskal-Wallis test
- Nominal (Categorical) Chi-square or Fisher's exact McNemar's test Chi-square test
- Hypothesis Testing, Type I/II Errors, and Statistical Power
Clinical trials are designed to test a hypothesis. The Null Hypothesis ( H 0 H_0 H 0 ) states that there is no difference between the treatment groups, while the Alternative Hypothesis ( H 1 H_1 H 1 ) states that a difference exists.
Type I Error ( α \alpha α )
A Type I error occurs when researchers reject a true null hypothesis, concluding that a difference exists when there is actually no difference (a false positive).
Alpha ( α \alpha α ): The maximum acceptable probability of committing a Type I error, set a priori, typically at 0.05. A p-value of < 0.05 < 0.05 < 0.05 indicates that the probability of the observed difference occurring by random chance under the null hypothesis is less than 5%.
Type II Error ( β \beta β ) and Statistical Power
A Type II error occurs when researchers fail to reject a false null hypothesis, concluding that no difference exists when a true therapeutic difference does exist (a false negative).
Beta ( β \beta β ): The probability of committing a Type II error, usually set at 0.10 or 0.20.
Statistical Power ( 1 − β 1 - \beta 1 − β ): The probability of correctly rejecting the null hypothesis and detecting a statistically significant difference if a true difference exists. A standard power target is 80% ( β = 0.20 \beta = 0.20 β = 0.20 ) or 90% ( β = 0.10 \beta = 0.10 β = 0.10 ).
Factors Influencing Statistical Power
Sample Size ( N N N ): As sample size increases, standard error decreases, which directly increases statistical power.
Effect Size: The magnitude of the difference between groups. Larger differences are easier to detect and require a smaller sample size to achieve the same power.
Variability (Standard Deviation): Greater variability or noise in the data (common in heterogeneous ICU populations) reduces power. Minimizing variability increases power.
Alpha Level ( α \alpha α ): Decreasing the acceptable Type I error rate (e.g., setting α = 0.01 \alpha = 0.01 α = 0.01 ) increases the risk of a Type II error, thereby reducing power.
To avoid conducting underpowered trials (which risk missing clinically beneficial treatments), investigators must perform an a priori power analysis to determine the minimum sample size required to detect a clinically meaningful effect size.
- P-values and Confidence Intervals
- P-values
A p-value is a continuous measure of evidence against the null hypothesis. However, p-values do not indicate the magnitude or direction of the treatment effect, nor do they reflect clinical relevance.
Confidence Intervals (CIs)
CIs provide a range of values within which the true population parameter is expected to lie with a specified probability (typically 95%). CIs are superior to p-values because they show the precision of the estimate, the direction of effect, and the clinical significance.
For Difference Measures (e.g., Mean Difference, Absolute Risk Reduction): If the 95% CI contains 0 (the null value for differences), there is no statistically significant difference between the groups ( p ≥ 0.05 p \ge 0.05 p ≥ 0.05 ).
For Ratio Measures (e.g., Relative Risk [RR], Odds Ratio [OR], Hazard Ratio [HR]): If the 95% CI contains 1.0 (the null value for ratios, indicating equal risk), there is no statistically significant difference ( p ≥ 0.05 p \ge 0.05 p ≥ 0.05 ). E.g., an OR for mortality of 0.82 with a 95% CI of [0.65 to 1.04] is not statistically significant.
Clinical vs. Statistical Significance
Statistical significance indicates that the observed difference is unlikely to be due to chance. It is heavily influenced by sample size: in very large studies, tiny differences can achieve a p-value < 0.05 < 0.05 < 0.05 .
Clinical Significance: Reflects whether the magnitude of the effect is large enough to impact patient care. For example, a trial enrolling 20,000 patients might find that a new vasoactive drug increases MAP by 0.7 mmHg compared to norepinephrine, with a statistically significant p-value of 0.002. However, a 0.7 mmHg change is clinically meaningless.
Minimum Clinically Important Difference (MCID): The smallest change or treatment effect that patients or clinicians perceive as beneficial. Clinicians must benchmark trial results against the MCID rather than relying solely on p-values.